Amgen Gets Broad Support In High Court Patent Fight
Massive drug companies, early-stage startups and a wide range of intellectual property groups were among many parties Tuesday urging the U.S. Supreme Court to hold that the Federal Circuit erred when...To view the full article, register now.
Already a subscriber? Click here to view full article